Stem cells bearing an FGF receptor on the cell surface

• US 6,767,737 B1
• Filed: 08/31/1999
• Issued: 07/27/2004
• Est. Priority Date: 08/31/1998
• Status: Expired due to Term

• Current Assignee: New York University
• Original Assignee: New York University
• Inventors: Wilson, E. Lynette, Burger, Patricia E.
• Primary Examiner(s): Lankford, Jr., Leon B.
• Application Number:
  US09/386,228
• Time in Patent Office: 1,792 Days
• Field of Search: 435/325, 435/372, 435/366
• US Class Current: 435/325
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: C12N 5/0647 Haematopoietic stem cells; Uncommitted or multipotent progenitors
• CPC Class Codes: C12N 5/0663 Bone marrow mesenchymal stem cells (BM-MSC)
• CPC Class Codes: C12N 5/0665 Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
• CPC Class Codes: C12N 5/0692 Stem cells; Progenitor cells; Precursor cells

Abstract

A composition of substantially purified pluripotent stem cells are positive both for fibroblast growth factor receptor (FGFR) and a phenotype indicative of a primitive state, such as CD34⁺, CD34⁻lin⁻, Thy-1⁺, AC133⁺ or c-kit⁺. The state of being an embryonic stem cell is also a phenotype indicative of a primitive state. This population may be further defined by the subpopulations thereof which have another marker thereon indicative of endothelial cells, such as TIE-1⁺, TEK⁺, CD31⁺, VE-Cadherin⁺ or VEGFR⁺ or indicative of stromal cells, such as STRO-1⁺.

Claims

1. A composition comprising a physiologically acceptable medium and human stem cells, wherein greater than 20% of said cells are human stem cells characterized as FGFR⁺ and also having another indicator of a primitive state, with the proviso that said human stem cells are not embryonic stem cells.

2. A composition in accordance with claim 1, wherein said indicator of a primitive state is selected from the group consisting of CD34⁺, CD34⁻

lin⁻

, Thy-1⁺, AC133⁺ and c-kit⁺.

3. A composition in accordance with claim 2, wherein said indicator of a primitive state is CD34⁺.

4. A composition in accordance with claim 2, wherein said indicator of a primitive state is CD34⁻

lin⁻

.

5. The composition according to claim 1, wherein said human stem cells are selected from the group consisting of endothelial stem cells, stromal stem cells and hematopoietic stem cells.

6. The composition according to claim 1, wherein greater than 20% of said cells are human stem cells characterized as FGFR⁺ and either CD34⁺ or CD34⁻

lin⁻

and further having one or more of the markers Thy-1⁺, AC133⁺ and c-kit⁺.

7. The composition according to claim 1, wherein greater than 20% of said cells are human stem cells characterized as FGFR⁺ and either CD34⁺ or CD34⁻

lin⁻

and further having one or more markers indicative of endothelial cells.

8. A composition in accordance with claim 7, wherein said markers indicative of endothelial cells are selected from the group consisting of TIE-1⁺, TEK⁺, CD31⁺, VE-Cadherin⁺ and VEGFR⁺.

9. The composition according to claim 1, wherein greater than 20% of said cells are human stem cells characterized as FGFR⁺ and either CD34⁺ or CD34⁻

lin⁻

and further having one or more markers indicative of stromal cells.

10. A composition in accordance with claim 9, wherein said marker indicative of stromal cells is STRO-1⁺.

11. The composition according to claim 7, wherein greater than 20% of said cells are human stem cells characterized as FGFR⁺ and either CD34⁺ or CD34⁻

lin⁻

and further having one or more markers indicative of endothelial cells.

12. The composition according to claim 6, wherein greater than 20% of said cells are human stem cells characterized as FGFR⁺ and either CD34⁺ or CD34⁻

lin⁻

and further having one or more markers indicative of stromal cells.

13. A composition in accordance with claim 1, wherein said human stem cells are a subpopulation of peripheral blood cells, bone marrow cells, or cord blood cells.

14. The composition according to claim 1, wherein greater than 90% of said cells are human stem cells characterized as FGFR⁺ and also having another phenotype indicative of a primitive state.

15. The composition according to claim 1, wherein greater than 90% of said cells are human stem cells characterized as FGFR⁺ and either CD34⁺ or CD34⁻

lin⁻

and further having one or more of the markers Thy-1⁺, AC133⁺ and c-kit⁺.

16. The composition according to claim 1, wherein greater than 90% of said cells are human stem cells characterized as FGFR⁺ and either CD34⁺ or CD34⁻

lin⁻

and further having one or more markers indicative of endothelial cells.

17. A composition in accordance with claim 16, wherein said markers indicative of endothelial cells are selected from the group consisting of TIE-1⁺, TEK⁺, CD31⁺, VE-Cadherin⁺ and VEGFR⁺.

18. The composition according to claim 1, wherein greater than 90% of said cells are human stem cells characterized as FGFR⁺ and either CD34⁺ or CD34⁻

lin⁻

and further having one or more markers indicative of stromal cells.

19. A composition in accordance with claim 18, wherein said marker indicative of stromal cells is STRO-1⁺.

20. The composition according to claim 6, wherein greater than 90% of said cells are human stem cells characterized as FGFR⁺ and either CD34⁺ or CD34⁻

lin⁻

and further having one or more markers indicative of endothelial cells.

21. The composition according to claim 6, wherein greater than 90% of said cells are human stem cells characterized as FGFR⁺ and either CD34⁺ or CD34⁻

lin⁻

and further having one or more markers indicative of stromal cells.

22. A composition in accordance with claim 14, wherein said human stem cells are a subpopulation of peripheral blood cells, bone marrow cells, or cord blood cells.

23. A cellular composition comprising a substantially homogeneous population of cultured human stem cells displaying a phenotype of FGFR⁺ and another phenotype indicative of a primitive state, which cells are capable of giving rise to cells selected from the group consisting of endothelial cells, stromal cells and hematopoietic cells, with the proviso that said cells are not embryonic stem cells.